Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus price target of $7.88 for the company and are predicting that the company will post ($0.19) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Viking Therapeutics an industry rank of 116 out of 265 based on the ratings given to related companies.
VKTX has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Viking Therapeutics in a report on Friday, November 10th. Maxim Group set a $8.00 price target on shares of Viking Therapeutics and gave the company a “buy” rating in a report on Tuesday, November 28th. Roth Capital initiated coverage on shares of Viking Therapeutics in a report on Tuesday, November 21st. They set a “buy” rating and a $5.00 price target for the company. Finally, ValuEngine downgraded shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st.
Viking Therapeutics (NASDAQ VKTX) opened at $4.06 on Friday. The company has a market cap of $152.16, a PE ratio of -4.83 and a beta of 1.87. Viking Therapeutics has a 1-year low of $0.88 and a 1-year high of $4.40.
Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). equities analysts predict that Viking Therapeutics will post -0.86 EPS for the current year.
WARNING: This news story was published by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://weekherald.com/2017/12/30/zacks-viking-therapeutics-inc-vktx-receives-consensus-rating-of-strong-buy-from-analysts.html.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.